Hollow-Fiber Ultrafiltration then Centrifugation for LC Analysis of Water-Soluble Sucrose in a Water-Soluble High-Molecular-Mass Gel Matrix

Ultrasound-assisted pH-shifting remodels egg-yolk low-density lipoprotein to enable construction of a stable aqueous solution of vitamin D3

Egg-yolk low-density lipoprotein (LDL) has a natural liposome structure. Using ultrasound-assisted pH-shifting (pH 12), a naturally safe and stable aqueous solution of vitamin D₃ (VD₃) was constructed employing LDL as the carrier. Images from electron microscopy showed that pH-shifting remodeled LDL molecules, resulting in a dramatic reduction in particle size (∼50%) and an increase in specific surface area, which reduced the turbidity (27.7%) and provided new interfaces for VD₃ loading. Fluorescence analyses showed that the binding of VD₃ to LDL under pH-shifting was strong, involved quenching, and the binding constant was 6.19 × 10⁴ M⁻¹. Thermogravimetric analysis and Fourier transform-infrared spectroscopy showed that pH-shifting hydrolyzed the esters in LDL to fatty acid salts, and the maximum weight loss of LDL occurred from 381.9 °C to 457.0 °C. Ultrasonic treatment enhanced the binding of LDL and VD₃ (binding constant increased to 2.56 × 10⁷ M⁻¹), reduced the particle size, and increased the ζ-potential of the complex between LDL and VD₃, thereby resulting in the improvement of solution stability and storage stability of VD₃. Ultrasound-assisted pH-shifting could remodel LDL to construct a stable aqueous solution of VD₃, which showed the potential of LDL as a carrier for lipid-soluble components.

•

pH-shifting remodels LDL and results in a reduction in particle size.

•

Under pH-shifting, VD₃ was bound stably to LDL with strong affinity.

•

pH-shifting remodeled LDL can be used to encapsulate active ingredients.

•

The binding of VD₃ to LDL was enhanced by ultrasonic treatment.

Development of a sample pretreatment device integrating ultrasonication, centrifugation and ultrafiltration, its application on rapid on-site screening of illegally added chemical components in heat-clearing, detoxicating Chinese patent medicines followed by electrospray ionization-ion mobility spectrometry

In this paper, a simple and rapid sample pretreatment device integrating ultrasonication, centrifugation and ultrafiltration (UCU) was reported for preparation of trace analytes in complex matrices. The UCU device was composed of two parts, A and B. The sample and extraction solvent were put into Part B for ultrasonic extraction. Subsequently, Part A and Part B were integrated and sealed for centrifugation and ultrafiltration. Finally, the ultrafiltrate in Part A was taken out for subsequent detection. After optimization, the device was applied to rapid on-site screening of five illegally added chemical components in heat-clearing and detoxicating Chinese patent medicines by combining with electrospray ionization-ion mobility spectrometry (ESI-IMS). The method showed good performance in terms of linearity with correlation coefficients (R²) above 0.9976 and limits of detection (LODs) in the range of 0.049-0.391 μg mL^-1. The recoveries were from 96.5 % to 100.8 %. The whole analysis process was within 11 min. The proposed method was further compared with other methods reported in the literature and the advantages and considerations were also explored. The results demonstrated that it was a simple, fast and accurate technique. The establishment of this method not only greatly improved the experimental efficiency but also avoided potential sample pollution brought by multiple sample transfer, and could provide a powerful means for rapid on-site analysis of trace analytes in complex matrices.

Sample preparation techniques for protein binding measurement in radiopharmaceutical approaches: A short review

Plasma protein binding (PPB) measurement is a key step in radiopharmaceutical studies for the development of positron emission tomography (PET) radioligands. PPB refers to the binding degree of a radioligand, radiotracer, or drug to blood plasma proteins or tissues after administration into the body. Several techniques have been successfully developed and applied for PPB measurement of PET radioligands. However, there is room for progress among these techniques in relation to duration time, adaptability with nonpolar radioligands, in vivo measurement, specificity, and selectivity. This mini review gives a brief overview of advances, limitations, and prospective applications of commercially-available PPB methods.

Plasma protein binding monitoring of therapeutic drugs in patients using single set of hollow fiber centrifugal ultrafiltration

Aim: Plasma protein binding (PPB), as a significant influenced factor of pharmacokinetic and pharmacodynamic properties of a medicine, is a suitable index for therapeutic drug monitoring (TDM) strategies. A suitable measurement technique of PPB of patients is in urgent need and attracts many analysts’ attention. Results & methodology: In this study, a novel method was proposed to analyze free drug concentration and total drug concentration (Ct) successively in one unit with a sample. All RSDs were less than 3%. The absolute recovery of Ct ranged from 98.1 to 101.2%. Discussion & conclusion: It is extremely valuable to consider PPB as an important index for TDM, perfecting information of medication, reflecting the disease condition more comprehensively, providing assistance for doctors to adjust the dose regimen. The proposed technique, convenience, accuracy and without the influence of plasma condition, provides a feasible method to monitor PPB of various patients, facilitating the popularization of monitoring PPB in TDM.

The significance of a new parameter – plasma protein binding – in therapeutic drug monitoring and its application to carbamazepine in epileptic patients

The primary cause of the variability of C_f in pharmacology is the change in plasma protein binding (PPB), thus PPB monitoring should be applied to a better individualization of drug dosage regimens in clinical patients.

Pretreatment of plasma samples by a novel hollow fiber centrifugal ultrafiltration technique for the determination of plasma protein binding of three coumarins using acetone as protein binding releasing agent

A novel and practical sample pretreatment method based on hollow fiber centrifugal ultrafiltration (HFCF-UF) was developed to determine plasma protein binding by using HPLC. The samples for analyzing unbound and total concentrations could be prepared in parallel simultaneously by the same device. It only required centrifugation for a short time and the filtrate could be injected directly for HPLC analysis without further treatment. Coumarins were selected as the model drugs. Acetone was chosen as the releasing agent to free the binding drug from the drug-protein complex for the total drug concentration determination. Non-specific bindings (NSBs) between the analytes and hollow fiber membrane materials were investigated. The type and volume of protein binding releaser were optimized. Additionally, centrifugal speed and centrifugal time were considered. Under the optimized conditions, the absolute recovery rates of the unbound and total concentrations were in the range of 97.5-100.9% for the three analytes. The limits of detection were in the range of 0.0135-0.0667μgmL(-1). In vitro plasma protein binding of the three coumarins was determined at three concentrations using the validated method and the relative standard deviations (RSDs) were less than 3.4%. Compared with traditional method, the HFCF-UF method is simple to run, no specialized equipment requirement and is a more accurate plasma pretreatment procedure with almost excellent drug-protein binding equilibrium. Therefore, this method can be applied to determine the plasma protein binding in clinical practice. It also provides a reliable alternative for accurate monitoring of unbound or total drug concentration in therapeutic drug monitoring (TDM).

Effect of volume ratio of ultrafiltrate to sample solution on the analysis of free drug and measurement of free carbamazepine in clinical drug monitoring

Traditional ultrafiltration (UF) usually has a large volume ratio of ultrafiltrate to sample solution, and this ratio cannot be well controlled. It can break the balance of protein-binding equilibrium and exert an influence on the analysis of free drug. In the present study, we evaluated the influence of volume ratio of ultrafiltrate to sample solution on the analysis of free drug in human plasma. We used carbamazepine as a model drug and studied the effect of different centrifugation times on ultrafitrate volume and the related effects on unbound carbamazepine measurement. Moreover, we compared the hollow fiber centrifugal ultrafiltration (HFCF-UF) with traditional UF. Our results showed that the ultrafiltrate volume was changed from 40 to 400 μL with the increase of centrifugation time for the traditional UF, and the related changes in unbound concentration were significant. The rate of protein binding (BP) was changed from 40% to 70%. In contrast, a tiny and invariant ultrafiltrate yield (40 μL) was obtained using the HFCF-UF method, and the BP rate was around 72%. In addition, with the HFCF-UF method, the volume ratio of ultrafiltrate to sample solution could be also well controlled by the inner diameters of both the glass tube and hollow fiber. The HFCF-UF method was a more accurate plasma pretreatment procedure, by which the in vivo balance of protein-binding equilibrium was hardly broken. Therefore, this method was successfully employed to quantify the free fraction of carbamazepine in clinical samples.